Sponsor

University Hospital, Gentofte, Copenhagen

Clinical research sponsor

Published trials98
Recruiting shown2
Roles2
SourceClinicalTrials.gov

Clinical trials

60 shown
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy HumansNCT07506369 · lead sponsor · 2026-04-01
RECRUITING
The Role of Oxytocin in Regulating Blood GlucoseNCT06334172 · lead sponsor · 2024-01-01
RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide TreatmentNCT07171723 · lead sponsor · 2025-09-01
COMPLETED
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in ObesityNCT06845033 · lead sponsor · 2025-05-01
ACTIVE_NOT_RECRUITING
Understanding How Gut and Brain Barriers Are Linked to Inflammation in ObesityNCT06787001 · lead sponsor · 2025-04-01
COMPLETED
The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 DiabetesNCT06881459 · lead sponsor · 2025-03-25
COMPLETED
Investigating Glucose Metabolism of LEAP2 With Total-body PET/CTNCT06254365 · lead sponsor · 2024-02-21
ACTIVE_NOT_RECRUITING
The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals with ObesityNCT06189001 · lead sponsor · 2024-01-01
COMPLETED
Dapiglutide for the Treatment of ObesityNCT05788601 · lead sponsor · 2023-04-27
ACTIVE_NOT_RECRUITING
Neuronostatin - a Glucagonotropic Agent in Humans?NCT06143267 · lead sponsor · 2022-12-06
COMPLETED
LEAP2 on Postprandial Glucose Metabolism and Food Intake n Obese MalesNCT05603598 · lead sponsor · 2022-08-24
UNKNOWN
The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 DiabetesNCT06137586 · lead sponsor · 2022-08-10
COMPLETED
LEAP2 Kinetics in Healthy IndividualsNCT04897984 · lead sponsor · 2021-05-24
COMPLETED
The Relationship Between Inflammatory ARTritis and CArdiac DIseAseNCT05647577 · lead sponsor · 2021-01-01
ACTIVE_NOT_RECRUITING
LEAP2 on Postprandial Glucose Metabolism and Food IntakeNCT04621409 · lead sponsor · 2020-11-17
COMPLETED
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 DiabetesNCT04228484 · lead sponsor · 2020-01-07
COMPLETED
The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin ResistanceNCT04315350 · lead sponsor · 2019-12-01
TERMINATED
The Role of Pregnancy-induced Gallbladder Dysmotility in the Pathophysiology of Gestational Diabetes MellitusNCT04108065 · lead sponsor · 2019-10-02
COMPLETED
Bariatric Surgery on NASHNCT04043585 · lead sponsor · 2019-07-31
COMPLETED
GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic PolypeptideNCT03845179 · lead sponsor · 2019-05-29
COMPLETED
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionNCT04061473 · lead sponsor · 2019-04-02
COMPLETED
Mind-Body Approaches for Medical ConditionsNCT03888261 · lead sponsor · 2019-04-01
UNKNOWN
Liver-enriched Antimicrobial Peptide 2NCT04043065 · lead sponsor · 2019-01-28
COMPLETED
GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food IntakeNCT03526289 · lead sponsor · 2017-11-08
COMPLETED
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small IntestinesNCT03241303 · lead sponsor · 2017-08-01
COMPLETED
Effect of GIP After a Meal in Patients With Type 2 DiabetesNCT03702660 · lead sponsor · 2017-08-01
COMPLETED
The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)NCT04064203 · lead sponsor · 2017-07-05
COMPLETED
The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaNCT03081676 · lead sponsor · 2017-03-08
COMPLETED
Investigation of Acute Physiological Effects of Aspiration TherapyNCT03389269 · lead sponsor · 2017-03-01
COMPLETED
Hypoglycaemia and Cardiac Arrhythmias in Type 2 DiabetesNCT03150030 · lead sponsor · 2017-02-01
COMPLETED
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 SecretionNCT03018444 · lead sponsor · 2016-10-01
COMPLETED
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsNCT02792400 · lead sponsor · 2016-05-01
COMPLETED
Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor AntagonismNCT02944110 · lead sponsor · 2016-04-01
UNKNOWN
Insulin Sensitivity in Patients With Atopic DermatitisNCT03003793 · lead sponsor · 2015-11-01
COMPLETED
Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 DiabetesNCT02669524 · lead sponsor · 2015-10-01
COMPLETED
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food IntakeNCT02598791 · lead sponsor · 2015-10-01
COMPLETED
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised SubjectsNCT02640118 · lead sponsor · 2015-08-01
COMPLETED
Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care SectorNCT02586545 · lead sponsor · 2015-08-01
COMPLETED
Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 DiabetesNCT02497313 · lead sponsor · 2015-07-01
COMPLETED
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon ClearanceNCT02475421 · lead sponsor · 2015-05-01
COMPLETED
Effect of Smoking on Postprandial Gastric Emptying, Glucose Tolerance and Secretion of Gut and Pancreatic HormonesNCT02497651 · lead sponsor · 2015-05-01
COMPLETED
Effect of Bile Acid Secretion and Sequestration on GLP-1 SecretionNCT02445508 · lead sponsor · 2015-05-01
COMPLETED
Outpatient Follow-up on Demand in Rheumatoid ArthritisNCT04476875 · lead sponsor · 2015-02-01
COMPLETED
Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut MicrobiotaNCT02061124 · lead sponsor · 2014-02-01
COMPLETED
The Role of Metformin and Colesevelam in Human GLP-1 SecretionNCT02050074 · lead sponsor · 2014-01-01
COMPLETED
Life Without DiabetesNCT02212665 · lead sponsor · 2014-01-01
COMPLETED
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose InfusionNCT02010827 · lead sponsor · 2013-11-01
COMPLETED
COPD-EXA-REHAB. Early Pulmonary Rehabilitation of Patients With Acute Exacerbation of COPDNCT02987439 · lead sponsor · 2013-11-01
COMPLETED
Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose DisposalNCT02006459 · lead sponsor · 2013-09-01
COMPLETED
Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated ExacerbationNCT01513655 · lead sponsor · 2013-07-01
UNKNOWN
Correlation Between Plasma- and Endothelial DPP-4 ActivityNCT02192853 · lead sponsor · 2013-05-01
COMPLETED
Effect of Bile Acids on GLP-1 SecretionNCT01666223 · lead sponsor · 2012-11-01
COMPLETED
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled TrialNCT01669395 · lead sponsor · 2012-09-01
UNKNOWN
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)NCT01610934 · lead sponsor · 2012-08-01
COMPLETED
Eradication of Gut MicrobiotaNCT01633762 · lead sponsor · 2012-04-01
COMPLETED
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes MellitusNCT01689051 · lead sponsor · 2012-03-01
COMPLETED
The Effect of GLP-1 on the Inhibition of Glucagon SecretionNCT01507597 · lead sponsor · 2011-12-01
COMPLETED
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without DiabetesNCT01492283 · lead sponsor · 2011-12-01
COMPLETED
Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes PatientsNCT01374594 · lead sponsor · 2011-06-01
COMPLETED
Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 DiabetesNCT03044860 · lead sponsor · 2011-03-01
COMPLETED

Sponsor roles

lead sponsor81
collaborator17

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.